Archive | Redefining Early Stage Investments RSS feed for this section

Apply Now to the Innovation Challenge for RESI Europe!

24 Jan

By Karen Deyo, Investor Research Analyst, LSN

With RESI SF behind us, we are looking forward to LSN’s first RESI in Europe. Taking place in Vienna, the inaugural RESI Europe will occur on March 25th at the Vienna Marriott Hotel. The application portal is now open for the RESI Europe Innovation Challenge.  For RESI San Francisco, LSN received over a hundred applications from startups featuring their new technologies, and we are excited to review your applications for RESI Europe.

Companies can apply through the online portal, with supplementary materials sent to The submission deadline is February 20th, 2019.

We will select the top 30 companies as finalists, giving them the opportunity to display a poster featuring their technology in the exhibit hall for the entire day. This will provide these companies with added exposure to the investor attendees. The Innovation Challenge is open to all early-stage companies, whether in therapeutics, diagnostics, medical devices or digital health.

In addition, we will feature 8 of the earliest-stage companies from regional tech hubs, incubators or accelerators in our Pitch Challenge. These companies will pitch in front of a panel of investors, giving them an opportunity to showcase their technology and gain feedback.

We look forward to receiving your application, and we hope to see you at RESI Europe!


RESI Europe: Check Out The Panel Agenda

24 Jan

By Lucy Parkinson, VP of Investor Research, LSN

RESI’s first Europe event will include three tracks of panel and workshop content aimed at educating entrepreneurs on key topics in life science capital raising.  RESI’s panels all feature experienced investors who can provide real-world insights to entrepreneurs and reveal their decision-making process and what catches their eye in a deal.

RESI Europe’s agenda includes our first ever panel on the Greater European Early-Stage Ecosystem, and a new combined look at Angels and Seed Funds to provide entrepreneurs with actionable insights for their first capital raise.  Popular special topic panels return, including AI in Healthcare and Microbiome, and two panels are focused on how to source investors from the Asia region – Asia Therapeutic Investors and Asia Corporates & Strategics.  Additionally, RESI Europe features panels on every major life science vertical and on some key investor types such as Family Offices and Corporate Venture Capital. If you’d like to attend these panels live, register for RESI Europe now.

Taiwan Investor Panel at RESI San Francisco, January 8th, 2019

24 Jan

By Jessica Yang, Senior Investor Research Analyst & Asia BD, LSN

Taiwan has been an important player and a pioneer in the world’s IT industry. Nowadays, through government support, Taiwan is also trying to establish its presence in life science industry, particularly in the Medical Device sector.

At RESI San Francisco during JPM week, LSN and BioMed TW cooperated to launch a new Taiwan Investor panel. The main purpose of this panel is to inform international startups’ on why Taiwan matters. We had the pleasure of inviting 6 panelists from Taiwan – all with a unique background related to Taiwan and working with early-stage innovations – to speak about their work and their perspectives on why international startups should approach Taiwan investors.

Our panelists included:

  • Michel Chu, General Partner, Acorn Campus Taiwan (Moderator)
  • Shaoyu Chang, Vice President, FC Capital
  • IC Jan, Director of Corporate Development, Taiwania Capital
  • Yi-Yen Chen, Investment Professional, WI Harper Group
  • Yuh-Geng Tsay, Venture Partner, Vivo Capital
  • William Tai, Managing Partner, Amed Ventures

Michel Chu, moderator of this panel, addressed the main question: How can Taiwan be a partner to an early-stage startup?

First, Taiwan can be seen as a manufacturing partner – medtech startups can look at Taiwan as a potential OEM/ODM partner. Taiwan is home to many global manufactures in the IT and semiconductor industry. Many of these highly-experienced IT manufacturers in Taiwan are also building medical devices. Thus, working with experienced manufacturers greatly reduces production and quality control risks. The panelists talked about “Design for Manufacturing” as something that is often overlooked by medtech startups – there is often a huge gap from prototype to final product, and the engineering work involved cannot be overlooked. Experienced manufacturers can help to re-engineer the product from a manufacturing perspective. Michel also mentioned that medical device manufacturing is all about quality control, and quality control should be built into the design from day one. Medtech startups should think of Design for Manufacturability (DFM), Design for Inspection (DFI) and Design for Assembly (DFA). In addition, Michel noted that it is becoming increasingly common for manufacturers to also invest in the medtech startups that contract them for their manufacturing needs.

The panel also discussed the fact that Taiwan recently passed legislation to allow people to collect fees from patients for experimental Phase II and Phase III cell therapies on a cost recovery basis. The panelists believe this will be attractive for companies that are planning clinical trials for cell therapies. Since clinical trials for cell therapies cost a fortune, placing some of the study centers in Taiwan may potentially save the company tens of millions of dollars. Also, Taiwan has some of the world’s most renowned hospitals and medical centers with modern facilities including GTP labs. The new regulation has already created a surge in clinical study plans by local and Japanese companies. Overall, the panelists mentioned that even though Taiwan itself is not a very sizable market, it may serve as an excellent strategic partner for global startups.

You can watch the full panel by clicking on this link!

%d bloggers like this: